Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Face Fit Bar Continues Partnership With Exclusive Haute Beauty Network


News Image

Lana Mar is on a mission to redefine beauty and make you fall in love with yourself. Face Fit Bar is not just a brand, it’s a movement!

Lana Mar is the owner and founder of the first Face Fitness Bar in Miami, the most unique concept of natural facelift that replaces fillers. Lana Mar is a skincare guru, educator, and certified Acne expert. After a severe allergic reaction to Botox, which is not very common, she was inspired to create an effective alternative.

As a former pro-athlete, Lana Mar believed in muscle memory and developed a Signature Hybrid massage with techniques from across the world in combination with cutting-edge technology and organic skin care. Since then, Face Fitness has become a movement with its shocking instant results, breaking the stereotype of plastics. Face Fitness was featured in Time Out Magazine as Miami’s Top 6 treatments of the year 2020.

Face Fit Bar enhances your best features and reminds you that what you perceive to be the negatives may very well be pluses. Lana Mar is on a mission to redefine beauty and make you fall in love with yourself. Face Fit Bar is not just a brand, it’s a movement!

Learn more about Face Fit Bar by visiting: https://hauteliving.com/hautebeauty/member/face-fit-bar/

ABOUT HAUTE BEAUTY NETWORK:

Haute Beauty is affiliated with the luxury lifestyle publication Haute Living. As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.

For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/

Share article on social media or email:

Dr. Vineet Sandhu Continues Partnership With Exclusive Haute MD Network


News Image

With Concierge MD NYC, Dr. Vineet is able to spend time with his patients and provide a specific high-end plan.

Born in NYC, and raised in NJ, Dr. Sandhu has traveled around the country for undergraduate school, medical school, and residency. He completed his Internal Medicine residency at Indiana University and then joined a large multi-care specialty group where he rapidly experienced many cases in a short amount of time. Now with roughly 10 years of medical experience, he is able to treat conditions ranging from congestive heart failure, COVID-19, diabetes, anxiety, bronchitis, sinusitis, and the common cold.

With Concierge MD NYC, Dr. Vineet is able to spend time with his patients and provide a specific high-end plan. He can work weekends and be on call 24/7 for your needs either in your home, in his office, or in telemedicine. The goal is to make healthcare more accessible to you, especially during these trying times and with your evolving needs. The focus is on you and your care.

Learn more about Dr. Vineet Sandhu by visiting: https://hauteliving.com/hautebeauty/mdmember/dr-vineet-sandhu/

ABOUT HAUTE MD NETWORK:

Haute Beauty is affiliated with the luxury lifestyle publication Haute Living. As a section of Haute Living magazine, Haute Beauty covers the latest advancements in health and wellness, providing readers with expert advice on aesthetic and medical treatments through its network of acclaimed doctors and beauty experts.

For more about Haute MD, visit https://hauteliving.com/hautebeauty/mdmember/

Share article on social media or email:

New Study Provides First Published Examples of Medication Deprescribing Protocols for Type 2 Diabetes


News Image

While guidelines do not yet exist for medication deprescribing in a lifestyle medicine context, these example protocols may be helpful for other clinicians seeking input on current best practices in deprescribing.

A qualitative case series research study sponsored by the American College of Lifestyle Medicine and published in Clinical Diabetes provides the first published examples of protocols to help guide clinical decision making on when and how to deprescribe medications following successful lifestyle medicine interventions to treat patients with type 2 diabetes.

The results of the case series are important because intensive therapeutic lifestyle change can lead to substantial and rapid decreases in blood sugar that result in hypoglycemia if prescription medications go unadjusted. However, limited relevant literature often leaves clinicians without adequate resources to help them deprescribe safely and effectively.

“The research team was able to document a variety of approaches that exist to successfully deprescribe glucose-lowering medications in a safe and effective way,” said Michael Bradley, PharmD, MPH, CDCES, CPH, who was first author on the paper. “As the practice of evidence-based lifestyle medicine to treat and attain remission of type 2 diabetes grows, these deprescribing protocols will become increasingly valuable to clinicians who are able to reduce the need for prescription medications and to their patients.”

Lifestyle medicine interventions are an emerging solution to the crisis of type 2 diabetes, which is the seventh leading cause of death in the United States. The Centers for Disease Control and Prevention (CDC) estimates that more than 34.2 million Americans have type 2 diabetes with an estimated cost in 2017 of $327 billion.

The American Diabetes Association and American Association of Clinical Endocrinology recommend lifestyle optimization as part of medical care for type 2 diabetes, and an expert consenus statement published in May reported multi-organizational agreement that dietary changes alone are capable of achieving remission in people type 2 diabetes.

For the study published in Clinical Diabetes, researchers conducted in-depth interviews of lifestyle medicine providers experienced in treating type 2 diabetes with the clinical goal of achieving remission. Most interviewees did not use a published protocol or algorithm for medication deprescribing, but rather shared their own decision-making process and protocols.

Among the key findings was that lifestyle medicine clinicians practice de-escalation of glucose-lowering medications when patients with type 2 diabetes develop a reduced need for pharmacotherapy, and that the clinicians often work in multidisciplinary teams of allied health professionals when deprescribing medications.

Medications that are often deprescribed first are those known to cause hypoglycemia as an adverse effect – often sulfonylureas or insulin – with a goal for patients to achieve normoglycemia, the study reported.

“While guidelines do not yet exist for medication deprescribing in a lifestyle medicine context, these example protocols may be helpful for other clinicians seeking input on current best practices in deprescribing,” said Micaela Karlsen, PhD, ACLM Senior Director of Research.

The authors called for the establishment of clinical practice guidelines and point-of-care tools for medication deprescribing, as well as clinician and patient education materials. The authors also recommended more research on health outcomes resulting from intensive therapeutic lifestyle interventions and comparisons of medication deprescribing practices.

About ACLM

The American College of Lifestyle Medicine is the nation’s medical professional society advancing lifestyle medicine as the foundation for a redesigned, value-based and equitable healthcare delivery system, leading to whole person health. ACLM educates, equips, empowers and supports its members through quality, evidence-based education, certification and research to identify and eradicate the root cause of chronic disease, with a clinical outcome goal of health restoration as opposed to disease management.

Share article on social media or email:

Northeast Delta Human Services Authority to host Drug Take-Back event on April 22


Northeast Delta Human Services Authority to host Drug Take-Back event on April 22

Northeast Delta Human Services Authority to host Drug Take-Back event on April 22

“Helping keep our communities safe by disposing of unwanted, unused, and expired medications is just one of many ways that NEDHSA is working to break the cycle of addiction and substance use disorder that plagues our region,” Dr. Sizer said.

Northeast Delta Human Services Authority (NEDHSA) will host a prescription drug take-back event on Saturday, April 22, from 10 a.m. to 2 p.m. in multiple locations throughout Northeast Louisiana.

NEDHSA will have teams stationed at the following locations:

  • Super 1 Foods, 2211 E. Madison Ave., Bastrop, LA 71220
  • Spring Market, 120 Legends Ave., Grambling, LA 71245
  • Brookshire’s, 1801 North 18th St., Monroe, LA 71201


NEDHSA Executive Director Dr. Monteic A. Sizer said, “Take Back Day events are important for us because they address our opioid crisis and reach the underserved rural areas of our region.”

“Helping keep our communities safe by disposing of unwanted, unused, and expired medications is just one of many ways that NEDHSA is working to break the cycle of addiction and substance use disorder that plagues our region,” Dr. Sizer said.

This event allows NEDHSA’s Opioid Misuse and Abuse Prevention Program team to educate the community about the risks of abuse of prescription and over-the-counter medications left unsecured in the home.

NEDHSA will accept pills, patches, and liquids but cannot accept needles, sharps, or aerosols. This service is free and confidential, with no questions asked.

Other locations individuals can properly dispose of prescription drugs are as follows:

  • East Carroll Parish Sheriff’s Office


400 First Street, Lake Providence, LA 71245

  • Grambling Police Department


2045 W Martin Luther King Jr. Ave., Grambling, LA 71245

  • Tallulah Police Department


500 East Green Street, Tallulah, LA 71282

  • Tensas Parish Sheriff’s Office


212 Hancock Street, St Joseph, LA 71366


700 Wood St., Monroe, LA 71201

  • ULM Police Department – Filhiol Hall


3811 DeSiard St, Monroe, LA 71209

  • Richwood Municipal Building


2710 Martin Luther King Drive, Richwood, LA 71202

  • Jonesboro Police Department


100 Fourth Street, Jonesboro, LA 71251

Share article on social media or email:

Smilyn Wellness Launches Biggest 420 Deal Ever Plus 50% Off Entire Order


News Image

Whether you’re a shop owner or someone who thoroughly enjoys hemp-derived products, chances are Smilyn has been on your radar. Here at Smilyn, we celebrate the amazing plant every day and 420 has become a focal part of our brand identity

From Tuesday, April 18th through Thursday, April 20th, Smilyn Wellness will be the top destination to find the best hemp deals for the epic 420 holiday.

“Whether you’re a shop owner or someone who thoroughly enjoys hemp-derived products, chances are Smilyn has been on your radar. Here at Smilyn, we celebrate the amazing plant every day and 420 has become a focal part of our brand identity. We wanted this year’s 420 campaign to expand to CBD customers and take over the online marketplace as a top destination for consumers to find the biggest deals for 420,” stated Howard Haber, General Manager of Smilyn Wellness.

The best day of the year for cannabis is right around the corner and so are all the deals and events that come along with it. Right now, Smilyn fans and new customers alike can take advantage of the huge BOGO $4.20 deal plus 50 percent off their entire order. The deals are so BIG, these products prices have never been seen before.

420 Smilyn Wellness Campaign ––

While cannabis lovers around the world have long observed 420 as the best holiday for getting high, the annual celebration is a longstanding Smilyn tradition and has now become the biggest day for legal hemp sales.

“Although a lot has changed in the hemp space over the last 5 years, we know one thing for sure, Smilyn consumers want to celebrate the occasion and we deliver on the deals,” stated Brett Weiss, CEO and Founder of Smilyn.

Future-Minded CBD and Delta Innovations ––

Smilyn Wellness has earned a reputation for creating future-minded CBD and delta innovations. From broad-spectrum CBD to a wide variety of recreational products, Smilyn offers the best experience while matching the needs of consumers across the board.

The Smilyn collection of in-demand, hemp-derived goodies are bursting with flavor, fun to consume, drive long-lasting results, and provide just the right amount of cannabinoid doses. This month, the California brand is set to unveil its new line of functional and euphoric mushrooms that provide powerful and pure solutions to nurture the body and elevate the mind.

About Smilyn Wellness

Smilyn Wellness in California is a CBD-wellness brand simplifying the benefits of premium hemp extract. We exist to revolutionize. We exist not only to help individuals look and feel amazing — but also smile throughout the adventures of life. Combining scientific data with health-based knowledge, Smilyn offers a portfolio of hemp-derived CBD and Delta products that are trustworthy, tasty, and geared toward an active new-age lifestyle.

Facebook | Instagram

Sale Terms:

*420 BOGO ITEM: 04.16.23 – 04.20.23 (CODE 420ITEM AUTOMATICALLY APPLIED)

*420 BOGO ITEM: BUY ONE ITEM GET ONE FOR $4.20 – LIMIT 1 PER ORDER

**Must Select Two Items for 420ITEM Discount to be Applied

**420 SALE 50% OFF ENTIRE ORDER: 04.18.23 – 04.20.23 (CODE 50OFF420 AUTOMATICALLY APPLIED)

Share article on social media or email:



The Importance of Ergonomics in the Dental Industry to Prevent Musculoskeletal Disorders


News Image

Ergonomic design is not a luxury; in the dental profession, it can prevent a career-ending injury

OSHA states that work-related musculoskeletal disorders (MSDs) are one of the most common reasons for missing work, the instances of which can be mitigated through the implementation of basic ergonomic principles in the workplace.(1) According to the CDC, work-related MSDs are injuries of the muscles, nerves, joints, or spinal discs sustained at work and exacerbated by the performance of one’s job.(2) MSDs are a pervasive affliction among dental health professionals affecting 64% to 93% of dentists and dental hygienists primarily due to prolonged static postures and repetitive movements.(3) Adrian LaTrace, CEO of Boyd Industries, observes, “A good dental provider does everything they can to relax their patients during any dental procedure, frequently at the expense of their own physical well-being. Dentists and hygienists assume awkward postures while performing repetitive tasks, positioning themselves rigidly in an effort to maintain precise movements so as to minimize patient discomfort. Ergonomic design is not a luxury; in the dental profession, it can prevent a career-ending injury.”

The World Health Organization affirms that musculoskeletal infirmities are the most reported disabilities worldwide, with lower back pain as the primary cause of disability in 160 countries.(4) Chronic musculoskeletal pain can lead to poor mental health leading to symptoms including anxiety, fatigue, depression, and insomnia. (5) MSDs in the dental profession have been shown to develop as early as dental school and are a harbinger of early retirement.(6) OSHA offers the “10 Principles of Ergonomics” training guidelines for the workplace, encouraging proactive remedies, such as maintaining neutral postures, reducing excessive force and motions, and working at the proper height; great advice, but impractical within the demands of the dental profession. (7) A lift-with-the-knees mentality fails to address the totality of the cause-and-effect predicament where conventional wisdom fails to resolve the problem.

Workplace ergonomics in the dental industry needs to be ubiquitous, from the front desk to the treatment chair and surrounding dental operatory equipment. It needs to be a holistic strategy that appreciates and anticipates every environmental factor that impedes efficiency and wellness. Boyd Industries, long known as the market leader in the design and manufacture of highly-reliable, innovative dental and medical operatory equipment, is renowned for its fine craftsmanship, ergonomic design, superior durability, and proven reliability. Boyd’s award-winning products include a full line of dental exam, treatment, and surgery chairs, delivery systems, exam lighting, custom clinical cabinetry, operator seating, and other office accessories.

Constantly hunching over patients can lead to musculoskeletal injuries of the neck and back. Boyd’s doctor and assistant seating comes in two height ranges with adjustable lumbar support to promote good posture. Dental treatment chairs with vertical lift adjustment in combination with dental operator chairs match optimal positioning for doctor comfort with one-touch memory settings for common patient positioning. Boyd’s mobile cabinetry, carts, and side units eliminate the fatigue of constantly reaching for equipment. Inadequate lighting causes eye strain and, over time, can lead to more serious vision issues. Boyd’s examination lighting moves freely and fully illuminates the oral cavity using natural white light, which has been proven to reduce eye fatigue.

LaTrace explains, “The benefits of an ergonomic office depend upon the individual needs of each member of the entire team; what might work for one might not work for another. Boyd provides customizable solutions to address the unique requirements of dental staff and patients.” With over 65 years of design and manufacturing expertise, Boyd creates the personalized products and equipment that dental specialists need. Made in the U.S.A., Boyd’s equipment is the #1 choice of Orthodontists, Oral Surgeons, Pediatric Dentists, Endodontists, and other dental professionals worldwide.

Built to last. Built for you. Built by Boyd.

About Boyd Industries

For 65 years, Boyd Industries has been the innovative market leader in the design and manufacture of dental and medical operatory equipment. Their high-quality and reliable equipment has been the choice of dental specialty practices and dental surgery offices. The rapidly expanding Ear, Nose, and Throat market now seeks its reputation for quality and innovation. Boyd equipment is specifically designed to provide maximum practice productivity while incorporating ergonomic characteristics for the doctor, staff, and patient. As an original equipment manufacturer, they use a vertically integrated approach to ensure their process meets high-quality standards. This approach allows Boyd to control each step of component fabrication and product assembly. Boyd’s products include a full line of dental exam, treatment, and surgical chairs, dental delivery systems, LED exam and surgical lighting, custom sterilization and storage cabinetry, and doctor or assistant seating. Boyd was named the Senate Small Business of the Week in November 2020 and is a ten-time winner of the Townie Choice Award for excellence in orthodontic operatory equipment. Boyd Industries is an FDA-registered manufacturer. Built to last. Built for you. Built by Boyd. http://www.boydindustries.com/.

References:

1. Department of Labor Logo United Statesdepartment of Labor. Ergonomics – Overview | Occupational Safety and Health Administration. (n.d.). Retrieved March 21, 2023, from osha.gov/ergonomics

2. Centers for Disease Control and Prevention. (2020, February 12). Work-related Musculoskeletal Disorders; Ergonomics. Centers for Disease Control and Prevention. Retrieved March 21, 2023, from cdc.gov/workplacehealthpromotion/health-strategies/musculoskeletal-disorders/index.html

3. Ludwig, E. A. (2022, September 23). Ergonomic equipment considerations for the dental hygienist – dimensions of Dental Hygiene: Magazine. Dimensions of Dental Hygiene | Magazine. Retrieved March 21, 2023, from dimensionsofdentalhygiene.com/article/ergonomic-equipment-considerations-for-the-dental-hygienist/

4. World Health Organization. (n.d.). Musculoskeletal health. World Health Organization. Retrieved March 21, 2023, from who.int/news-room/fact-sheets/detail/musculoskeletal-conditions#:~:text=Approximately%201.71%20billion%20people%20have,of%20disability%20in%20160%20countries

5. Garnæs, K. K., Mørkved, S., Tønne, T., Furan, L., Vasseljen, O.; Johannessen, H. H. (2022, December 22). Mental health among patients with chronic musculoskeletal pain and its relation to number of pain sites and pain intensity, a cross-sectional study among primary health care patients – BMC musculoskeletal disorders. BioMed Central. Retrieved March 21, 2023, from bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-022-06051-9

6. NN, L. (n.d.). Work-related musculoskeletal disorders in dental students: A cross-sectional, pilot study from a UK University Teaching Hospital. Work-Related Musculoskeletal Disorders in Dental Students: A Cross-Sectional, Pilot Study from a UK University Teaching Hospital. Retrieved March 21, 2023, from clinmedjournals.org/articles/jmdt/journal-of-musculoskeletal-disorders-and-treatment-jmdt-6-079.php

7. Home | occupational safety and health administration. (n.d.). Retrieved March 22, 2023, from osha.gov/sites/default/files/2018-11/fy12_sh-23543-12_ErgoforTrainers-TTTProgram.pdf

Share article on social media or email:

Trialbee to Share a Pragmatic Guide for European Clinical Trial Patient Recruitment in Upcoming Webinar


News Image

Trialbee’s European heritage, expert leadership in the U.K. and the U.S., and unique perspective on global patient recruitment allow speakers to offer best practices, channels, and strategies that can be applied throughout Europe and the rest of the world.

Trialbee, the leader in data and technology-based patient recruitment for global clinical trials, will present “European Patient Recruitment: A Pragmatic Guide,” an informational webinar that focuses on ensuring successful results in specific countries and patient pools.

The 30-minute webinar will be held on April 26 at 4pm CEST (10am EST) and led by Trialbee subject matter expert Joanna Auerbach-Rodriguez, Senior Director of Digital Marketing, with CEO Matt Walz.

Auerbach-Rodriguez and Walz will leverage the company’s European heritage, its expert leadership in the U.K. and the U.S., and its unique perspective on global patient recruitment to offer best practices, channels, and strategies that can be applied throughout Europe and the rest of the world.

Click here to register to attend the webinar.

Topics to be discussed include:

  • Global outreach strategies that work — and country-specific challenges to overcome
  • Centralizing metrics for an entire global campaign with reporting in Trialbee Honey™
  • The growing importance of tailoring online tactics and messaging for international participants
  • The business imperative of earlier and sustained patient engagement.

“Patient recruitment in clinical trials is a dynamic, complex process — and country-specific regulations and behaviors only make it more complicated,” Auerbach-Rodriguez said. “Our success in identifying and recruiting patients across Europe will provide sponsors and CROs who are seeking to optimize their recruitment efforts across diverse markets with a blueprint that can lead to successful clinical trial outcomes.”

After the webinar concludes, a recording will be provided to those who registered for on-demand viewing.

About Trialbee

Trialbee is the leading global data and technology platform for patient recruitment and enrollment in clinical trials. Trialbee Hive™ operationalizes real-world data (RWD) and applies data science to find patients globally. Trialbee Honey™ simplifies the journey into clinical research for patients, reduces the burden of enrolling patients for sites, and provides real-time, data-driven insights to sponsors and CROs so they can optimize enrollment timelines. Partnering with sponsors, CROs, and virtual/decentralized sites and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at solutions@trialbee.com.

Share article on social media or email:

DDL Implements a GMP compliant quality system at its CA Lab for its CCIT division


DDL is now able to perform CCI testing on sterile package systems for parenteral drug and biologic products that meet GMP regulatory requirements.

DDL, Inc. announced today that it has implemented a GMP compliant quality system at its Irvine, CA laboratory to govern its container closure integrity testing (CCIT) division.

Container closure integrity testing evaluates the effectiveness of a package system’s seal or closure to maintain its sterile barrier over a product’s shelf life. CCI testing is a crucial regulatory requirement in ensuring the quality and safety for pharmaceutical products, as any breach in the package system can compromise the product’s stability and sterility. With the addition of the new quality system, DDL is now able to perform CCI testing on sterile package systems for parenteral drug and biologic products that meet GMP regulatory requirements.

“As the pharmaceutical industry technologies advance, particularly with sterile package systems and novel administration methods, ensuring our quality management system meets or exceeds the industry requirement will provide a higher degree of confidence and reliability for our customer’s regulatory submissions and filings,” said Michael Dominguez, DDL CCIT program manager. “Having a quality system that harmonizes with the multiple regulatory bodies across the globe will help ease the navigation and approach to the regulatory challenges our customers are facing, and ultimately instill a higher value of service for their programs.”

DDL will showcase its CCI testing, as well as its package, medical device and material testing service offerings in Booth #1253 at the INTERPHEX conference being held April 25-27 at the Javits Center in New York, NY. For more information on DDL’s testing services, or to receive a quote, please contact DDL at DDLinfo@ddltesting.com or call us at 800-229-4235.

About DDL

DDL is a third party independent testing facility that offers expertise in medical device, materials and package testing primarily serving the life sciences industry. DDL’s testing laboratories are located in Eden Prairie, MN, Irvine, CA and Edison, NJ. Visit https://www.DDLTesting.com for more information about the testing services offered by DDL.

Share article on social media or email:

The deal pairs Vyne Dental’s web-based dental revenue acceleration platform, Vyne Trellis, with Simplifeye’s advanced technology for next-generation payment processing


News Image

“Joining the Vyne Dental team will help us continue blazing a new, better path in the industry, delivering on our promise to provide world-class services to practices across the retail healthcare landscape,” shared Dr. Ryan Hungate, founder of Simplifeye.

As an industry innovator, Simplifeye creates practice efficiency and a modernized patient experience by transforming how practices process billing and payments. With end-to-end payment tools that include automated payment workflows and customized payment plans, the organization additionally delivers optimized user solutions with its Amplify 24/7 chat and direct scheduling features.

The unparalleled pairing with Vyne TrellisⓇ, Vyne Dental’s comprehensive, web-based dental billing platform helping dental practices accelerate their revenue cycles, creates a revolutionary fusion of technologies that will bring innovation to dental billing and payment processing. Set to transform how the dental industry processes payments, the integration of Simplifeye’s tools enables Vyne Dental to further optimize its unprecedented revenue cycle acceleration platform.

“Vyne Dental’s mission-driven approach is aligned with Simplifeye,” shared Dr. Ryan Hungate, founder of Simplifeye. “Joining the Vyne Dental team will help us continue blazing a new, better path in the industry, delivering on our promise to provide world-class services to practices across the retail healthcare landscape.”

This acquisition furthers Vyne Dental’s mission of simplifying the process of claims and attachment management and accelerating revenue growth for dental practices. “Their next-gen billing and payments platform is groundbreaking. Their innovation in this field was unparalleled, and we are confident that their acquisition will bring tremendous value to our organization,” said Steve Roberts, Chief Executive Officer at Vyne. “By incorporating their cutting-edge technology, we are poised to revolutionize the way dental practices manage their revenue cycle and drive our mission as a leader in revenue acceleration.”

Leaders in dental will join Vyne Dental and Simplifeye teams this May 10-12 for AMPLIFY, an industry-leading conference offering an experience unlike any other, in Charleston, SC. In the era of AI, automation, disruption, and change management, the brightest minds in healthcare operations will convene to demystify technology adoption. Attendees will experience insightful mastermind sessions and leave with ideas that drive results. DSO Executives and doctors can use promo code: VYNE100 to receive $100 off registration*(terms and conditions apply) at http://www.amplifycon.com.

Vyne Dental has emerged as a solution of choice for revenue cycle acceleration in the dental industry, bolstered by its strategic acquisitions of NEA (National Electronic Attachment), Renaissance Electronic Services, Tesia Clearinghouse, OperaDDS, Onederful, and now Simplifeye. With a promising future ahead, the company is poised for continued growth.

About Simplifeye

Simplifeye empowers doctors by automating the business side of their practices. The company provides software solutions that digitize and improve existing processes that are core to many medical practices. Simplifeye allows medical professionals to focus their efforts on providing high-quality health care, resulting in great experiences for patients. The company currently serves 8,000 practices and has facilitated more than 400,000 patient appointments. For more information or a Simplifeye demo, visit https://simplifeye.co.

About Vyne Dental

Vyne Dental is part of the Vyne® family, providing end-to-end health information exchange and electronic healthcare communication management for more than 800 hospitals and health systems, 74,000 dental offices, and more than 800 plans and payers across the United States. Uniquely positioned to serve multiple key stakeholders within healthcare, Vyne has made Inc. 5000’s annual list of the nation’s most prestigious and fastest-growing private companies for 15 consecutive years. Under Steve Roberts, Vyne continues leveraging synergies across its two health tech businesses, Vyne Medical and Vyne Dental, to accelerate growth and facilitate relationships between providers, payers and patients across the full healthcare spectrum.

Vyne Dental continues to advance the dental industry by providing technology that improves workflow, reduces administrative costs, and streamlines reimbursements. For more information visit http://www.vynedental.com.

© 2023 Napa EA/MEDX LLC. All rights reserved. All third-party trademarks and tradenames (including logos and icons) referenced are and remain the property of their respective owners. Hyperlinks included are provided for convenience and may lead to resources located on servers maintained by other persons or organizations. Vyne is not responsible for the privacy practices of third-party websites.

Share article on social media or email:

MatTek Life Sciences and NEXT Oncology Announce Licensing Agreement to Develop Lab-Grown Tumors


“Using the panel of cancer types, we will develop a drug screening protocol that can determine effective drugs for specific cancer types and be applied for personalized medicine,” said Dr. Anthony Tolcher, CEO and founder of NEXT Oncology.

MatTek Life Sciences and NEXT Oncology jointly announced today a licensing agreement that will have MatTek turn NEXT Oncology’s patient tumor cells into laboratory-grown in vitro tumor models for cancer research. With locations in Texas, Virginia, and Spain, NEXT Oncology is a global network of Phase I cancer research clinics dedicated to providing patients access to the latest treatments for advanced cancers. MatTek Life Sciences, a Boston-based biotech company, is a leader in the production of lab-grown human tissues and organs used worldwide as human-relevant replacements for animal testing.

NEXT Oncology holds a unique inventory of primary cancer cells from donor patients diagnosed with aggressive, rare, and advanced cancers. Most patients had been treated with best-in-class oncological therapies that were ineffective in battling the disease.

“Using the panel of cancer types, we will develop a drug screening protocol that can determine effective drugs for specific cancer types and be applied for personalized medicine,” said Dr. Anthony Tolcher, CEO and founder of NEXT Oncology. “The tumor models reflect the unmet needs of patients with cancer, and therefore more closely represent the important models for new drug development. We welcome the opportunity to work with MatTek so that pharma and biotech companies can access relevant models to advance more meaningful treatment options for patients.”

The conventional method of creating in vitro tumor models by using cancer cell lines has been useful for cancer research, but these models lack the complexity and heterogeneity of tumors in the body. Tumor models created from primary cells excised from patient tumors can better replicate the tumor microenvironment, including its cellular and extracellular components. These tumor models can then be used to study the genetic and molecular characteristics of the tumor, test the effectiveness of various cancer treatments, and explore the underlying mechanisms of cancer.

MatTek’s state of the art labs, established and rigorous quality standards, and staff expertise in growing human tissues from primary donor cells make it a natural fit to produce and scale-up production of these new tumor models. The company’s R&D team will be working to create ten types of lab-grown tumor tissues immediately and expect the first models to be commercially available by July of this year. “We have already had great success expanding the cells, and initial production shows excellent cellular structure and responsiveness,” said Dr. Seyoum Ayehunie, MatTek’s chief scientific officer. “These tissues will provide cancer researchers and cancer drug developers with the best tools available to evaluate therapeutic responses.”

The technology is still in its early stages, but the potential benefits are significant. By replicating the tumor microenvironment more accurately, these models will help researchers better understand the biology of cancer and could potentially lead to the development of new treatments that are tailored to individual patients.

About MatTek Life Sciences

Founded in 1985, MatTek Life Sciences began producing three-dimensional human tissue models as reliable replacements for animal testing. MatTek’s physiologically advanced tissue models empower companies in the cosmetics, chemical, and pharmaceutical industries to achieve their goals of non-animal testing while lowering preclinical costs and providing human-relevant results. With locations in the US and Europe, today MatTek’s offerings include skin, eye, oral, respiratory, vaginal, and intestinal tissue models including disease modeling, validated, and custom testing services, multiple donor primary cells, culture media, and highly optical cultureware.

About NEXT Oncology

NEXT Oncology is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option. NEXT is partnered with Texas Oncology, the largest private oncology practice in the United States with more than 400 referring oncologists and US Oncology, a network of independent, community-based oncologists in the U.S. This formidable size and reach provide NEXT unprecedented opportunities to transform what has come to be expected from clinical trials of new agents.

Share article on social media or email: